By the Top Tier Newswire AI Desk · July 17, 2026 at 10:56 AM ET · reviewed against 4 wire stories
VERADERMICS INC (MANE) is up +8.09% in the latest session. Our newswire has captured 4 stories on MANE across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 63/100).
Veradermics Inc (MANE) shares surged 8.09% to $114.41 in a volatile session driven by positive developments in the company’s clinical trials for hair-loss treatments. The stock opened with a 4.9% gap up and reached an intraday high of $116.75 before consolidating gains. The rise follows the release of data from a subgroup analysis of its Phase 2/3 trial for VDPHL01, which showed early results in both male and female participants.
What Happened
Veradermics announced the presentation of data from a subgroup analysis of its Phase 2/3 Study 302, which evaluated VDPHL01 in males with pattern hair loss. The study is part of a broader clinical program for the extended-release oral minoxidil treatment. Separately, data from a Phase 2 trial of VDPHL01 in female subjects showed an increase in hair count as early as the second month of treatment. These developments have generated optimism about the drug’s potential in both male and female hair-loss markets. The company is also funded through 2030, providing visibility for continued development. Citigroup and Needham recently raised their price targets for MANE to $160 and $164 respectively, maintaining Buy ratings.
What The Data Shows
MANE opened at $111.00, a 4.9% gap up from the prior close, and traded as high as $116.75 before settling at $114.18. The session saw a low of $105.01, reflecting early volatility. Trading volume reached 0.2 million shares, which is 0.3 times the 3-month average. The stock is currently trading within its 52-week range of $32.00 to $131.24. Despite a market cap of $4.6 billion, the company remains unprofitable, with an EPS of -15.84 for the trailing twelve months.
What To Watch
Veradermics is expected to report top-line results from Study 304 in the second half of 2026. Investors will also monitor the breadth of analyst coverage and any further updates on clinical trial progress.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Not financial advice.
MANE · Jul 17 session (5-min) · +6.66% vs prior close · updated 9:00 PM ETAI sentiment, last 36h · averaged over 4 stories · 63/100 bullish
The headlines behind the move
Story flow · 4 stories on the wire, last 36h · hover or tap a dot for the headline
12d agoSeeking AlphaBULLISH 63Product/PR
Veradermics: VDPHL01 Looks Promising Enough On Paper
Veradermics, Incorporated’s VDPHL01 hair-loss drug shows promising data, targets a large cash-pay market, and is funded into 2030. Learn more about MANE stock here.
12d agoStockTitanBULLISH 63Product/PR
Veradermics Announces Presentations of Data from a Subgroup Analysis of Phase 2/3 Study ‘302’ in Males with Pattern Hair Loss at 2026 American Academy of Dermatology Innovation Academy | MANE Stock News
Study 302 is a randomized, double-blind, placebo-controlled trial in over 500 males evaluating extended-release oral minoxidil; Study 304 topline results are anticipated in 2H 2026.
14d agoStocktwits NewsBULLISH 63Product/PR
Why Is MANE Stock Rising Today?
In Veradermics’ Phase 2 trial for VDPHL01, female subjects showed an increase in hair count as early as the second month of treatment.
14d agoInvestorsHubBULLISH 63Product/PR
Veradermics shares climb 9% after encouraging female hair loss trial results (MANE)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →